Experimental cell therapy takes on multiple sclerosis
NCT ID NCT07546110
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment for multiple sclerosis (MS) that combines a drug called ofatumumab with NK042, a therapy made from immune cells donated by healthy people. The study will include 20 adults with different types of MS and will primarily check for safety and side effects. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NK042 cells (immune cells from healthy donors) and ofatumumab (a drug that targets B cells)
- What this could lead to
- If it works, this could point toward a new way to control multiple sclerosis by resetting the immune system.
- What could go wrong
- This is a very early, small trial (20 people) focused on safety, not proof of effectiveness. The combination may cause side effects or fail to improve symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?